ACM
SNDX icon

Asymmetry Capital Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Asymmetry Capital Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-135,974
Closed -$1.94M – 43
2018
Q1 		$1.94M Buy
135,974
+74,444
+121% +$790K 2.42% 15
2017
Q4 		$539K Buy
+61,530
New +$609K 0.73% 27
2017
Q2 		– Sell
-60,087
Closed -$824K – 35
2017
Q1 		$824K Buy
+60,087
New +$624K 1.15% 21

Other funds holding SNDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Asymmetry Capital Management's SNDX Position: Q2 2018 in Review

Asymmetry Capital Management sold out of Syndax Pharmaceuticals (SNDX) in Q2 2018, closing a stake of 135,974 shares — an estimated $1.94M sold.

Asymmetry Capital Management first reported a position in SNDX in Q1 2017 and held it in 3 quarters. The position peaked at $1.94M in Q1 2018. 84 funds tracked by Wall St. Rank hold SNDX as of Q2 2018.

  • Asymmetry Capital Management reported no remaining Syndax Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Asymmetry Capital Management sold 135,974 Syndax Pharmaceuticals shares in Q2 2018, an estimated $1.94M.
  • Asymmetry Capital Management first reported a position in Syndax Pharmaceuticals in Q1 2017 and held it in 3 quarters.
  • Asymmetry Capital Management's Syndax Pharmaceuticals position peaked at $1.94M in Q1 2018.
  • 84 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2018.

Based on Asymmetry Capital Management's 13F filing for Q2 2018, filed 7 Aug 2018.